Author
Listed:
- Jing Qi
(College of Pharmaceutical Sciences, Zhejiang University)
- Feiyang Jin
(College of Pharmaceutical Sciences, Zhejiang University)
- Yuchan You
(College of Pharmaceutical Sciences, Zhejiang University)
- Yan Du
(College of Pharmaceutical Sciences, Zhejiang University)
- Di Liu
(College of Pharmaceutical Sciences, Zhejiang University)
- Xiaoling Xu
(College of Pharmaceutical Sciences, Zhejiang University)
- Jun Wang
(College of Pharmaceutical Sciences, Zhejiang University)
- Luwen Zhu
(College of Pharmaceutical Sciences, Zhejiang University)
- Minjiang Chen
(College of Pharmaceutical Sciences, Zhejiang University)
- Gaofeng Shu
(Lishui Hospital of Zhejiang University)
- Liming Wu
(The First Affiliated Hospital, Zhejiang University School of Medicine)
- Jiansong Ji
(Lishui Hospital of Zhejiang University)
- Yongzhong Du
(College of Pharmaceutical Sciences, Zhejiang University)
Abstract
Some specific chemotherapeutic drugs are able to enhance tumor immunogenicity and facilitate antitumor immunity by inducing immunogenic cell death (ICD). However, tumor immunosuppression induced by the adenosine pathway hampers this effect. In this study, E-selectin-modified thermal-sensitive micelles are designed to co-deliver a chemotherapeutic drug (doxorubicin, DOX) and an A2A adenosine receptor antagonist (SCH 58261), which simultaneously exhibit chemo-immunotherapeutic effects when applied with microwave irradiation. After intravenous injection, the fabricated micelles effectively adhere to the surface of leukocytes in peripheral blood mediated by E-selectin, and thereby hitchhiking with leukocytes to achieve a higher accumulation at the tumor site. Further, local microwave irradiation is applied to induce hyperthermia and accelerates the release rate of drugs from micelles. Rapidly released DOX induces tumor ICD and elicits tumor-specific immunity, while SCH 58261 alleviates immunosuppression caused by the adenosine pathway, further enhancing DOX-induced antitumor immunity. In conclusion, this study presents a strategy to increase the tumor accumulation of drugs by hitchhiking with leukocytes, and the synergistic strategy of chemo-immunotherapy not only effectively arrested primary tumor growth, but also exhibited superior effects in terms of antimetastasis, antirecurrence and antirechallenge.
Suggested Citation
Jing Qi & Feiyang Jin & Yuchan You & Yan Du & Di Liu & Xiaoling Xu & Jun Wang & Luwen Zhu & Minjiang Chen & Gaofeng Shu & Liming Wu & Jiansong Ji & Yongzhong Du, 2021.
"Synergistic effect of tumor chemo-immunotherapy induced by leukocyte-hitchhiking thermal-sensitive micelles,"
Nature Communications, Nature, vol. 12(1), pages 1-17, December.
Handle:
RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-24902-2
DOI: 10.1038/s41467-021-24902-2
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-24902-2. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.